Integra LifeSciences implanted the first Cadence® Total Ankle as part of a non-randomized, prospective, multi-center postmarket study.
The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.
Since initial clinical use in 2Q16, >350 Cadence procedures have been performed in seven countries, including Europe and the U.S.; this is an increase from 200 performed by the end of 1Q17. Key design features of Cadence include:
- Side-specific, anatomical tibial components, intended to avoid fibular impingement
- Side-specific, anatomical talar components, intended to minimize resected talar bone and preserve vascularity
- Highly crosslinked ultra-high molecular weight polyethylene (HXL UHMWPE) bearing insert components for improved wear, and patent pending-biased sagittal profile options to address subluxed talar anatomy
Sources: Integra LifeSciences; clinicaltrials.gov; ORTHOWORLD Inc.
Image courtesy of Integra LifeSciences